• Oncolytics Biotech today reported updated GOBLET trial results for pelareorep with atezolizumab in previously treated advanced squamous cell anal cancer.
• Responses lasted longer than historical results for FDA-approved retifanlimab monotherapy, supporting further development of the combination.
• Following FDA Fast Track designation, additional studies with a potential checkpoint inhibitor partner could support registration, including possible accelerated approval.
• A similar combination study in HPV-associated head and neck cancer is under consideration, extending the drug’s potential development beyond anal cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270930PRIMZONEFULLFEED9853575) on October 27, 2026, and is solely responsible for the information contained therein.